RECRUITING

Total Intravenous Anesthesia (TIVA)/Sevoflurane Initiated Intravenous Anesthesia (SIIVA) in Pediatric Patients

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Because Propofol is the primary "anesthetic agent," and inhalational agents remain in trace quantities at the end of the procedure Sevoflurane initiated intravenous anesthesia (SIIVA) or not present at all Total intravenous anesthesia (TIVA) it is likely that different criteria may be predictive of extubation success in these patients compared to inhalational anesthesia.

Official Title

A Prospective Observational Study Evaluating Extubation Criteria in Children Less 10 Years of Age and Younger Undergoing Intravenous Anesthesia

Quick Facts

Study Start:2023-03-28
Study Completion:2028-03
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05837936

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:Not specified to 9 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD
Inclusion CriteriaExclusion Criteria
  1. * Pediatric patients \<10 years of age
  2. * Undergoing elective or emergency surgery with planned airway instrumentation with an endotracheal tube (ETT)
  3. * Patients having general anesthesia with a planned SIIVA or TIVA technique
  4. * Patients with an end tidal agent concentration of Sevoflurane\<0.1% at the time of emergence and extubation
  5. * following sevoflurane induction to place IV
  1. * History of home oxygen use or ventilator dependence
  2. * Patients with cyanotic congenital heart disease
  3. * Patients undergoing anesthesia for imaging procedures alone
  4. * Patients intended to be managed with supraglottic airway
  5. * Patients having an anesthesia time \< 30 minutes
  6. * Monitored Anesthesia Care (not general anesthesia)
  7. * Patients with contraindication to receiving Propofol (i.e. mitochondrial myopathy)

Contacts and Locations

Study Contact

Wes Templeton, MD
CONTACT
336-716-4498
ttemplet@wakehealth.edu
Lynne Harris, BSN
CONTACT
336-716-8791
lcharris@wakehealth.edu

Principal Investigator

Thomas "Wes" Templeton, MD
PRINCIPAL_INVESTIGATOR
Wake Forest University Health Sciences

Study Locations (Sites)

Atrium Health Wake Forest Baptist
Winston-Salem, North Carolina, 27157
United States

Collaborators and Investigators

Sponsor: Wake Forest University Health Sciences

  • Thomas "Wes" Templeton, MD, PRINCIPAL_INVESTIGATOR, Wake Forest University Health Sciences

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-03-28
Study Completion Date2028-03

Study Record Updates

Study Start Date2023-03-28
Study Completion Date2028-03

Terms related to this study

Keywords Provided by Researchers

  • anesthesia
  • Propofol
  • inhalational agents

Additional Relevant MeSH Terms

  • Extubation